The Technical Analyst
Select Language :
Innoviva Inc [INVA]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Innoviva Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: SELL (auto-tracking)

Innoviva Inc is listed at the  Exchange

-0.33% $15.24

America/New_York / 28 mar 2024 @ 16:00


FUNDAMENTALS
MarketCap: 963.58 mill
EPS: 2.20
P/E: 6.93
Earnings Date: May 06, 2024
SharesOutstanding: 63.23 mill
Avg Daily Volume: 0.685 mill
RATING 2024-03-28
S
Strong Buy
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Strong Buy
Return On Asset: Strong Buy
DE: Strong Buy
P/E: Strong Buy
Price To Book: Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE 6.93 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
1.18x
Company: PE 6.93 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 14.81 - 15.67

( +/- 2.85%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-03-05 Basso Stephen Buy 25 899 Non-statutory Stock Option
2024-03-05 Basso Stephen Buy 12 096 Common Stock
2024-03-05 Ronsheim Matthew Buy 27 338 Non-statutory Stock Option
2024-03-05 Ronsheim Matthew Buy 12 768 Common Stock
2024-03-05 Zhen Marianne Buy 23 022 Non-statutory Stock Option
INSIDER POWER
89.89
Last 96 transactions
Buy: 2 118 652 | Sell: 32 343 813

Forecast: 16:00 - $15.24

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $15.24
Forecast 2: 16:00 - $15.24
Forecast 3: 16:00 - $15.24
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $15.24 (-0.33% )
Volume 0.450 mill
Avg. Vol. 0.685 mill
% of Avg. Vol 65.67 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Innoviva Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Innoviva Inc

RSI

Intraday RSI14 chart for Innoviva Inc

Last 10 Buy & Sell Signals For INVA

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:35buy$15.60N/AActive
Profile picture for
            Innoviva Inc

INVA

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Last 10 Buy Signals

Date Signal @
XVSUSDMar 28 - 19:42$16.07
NEXOUSDMar 28 - 19:431.343
MATICUSDMar 28 - 19:43$1.002
BTCUSDMar 28 - 19:44$70 722
ANTUSDMar 28 - 19:38$9.05
BARUSDMar 28 - 19:383.69
DUSKUSDMar 28 - 19:380.605
BTGUSDMar 28 - 19:36$49.83
STXUSDMar 28 - 19:35$3.44
INJUSDMar 28 - 19:3438.22

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.